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Abstract The purpose of the present study is to examine
HFE gene mutations in relation to newly diagnosed (inci-
dent) coronary heart disease (CHD). In a population-based
follow-up study of 7,983 individuals aged 55 years and
older, we compared the risk of incident CHD between HFE
carriers and non-carriers, overall and stratiﬁed by sex and
smoking status. HFE mutations were signiﬁcantly associ-
ated with an increased risk of incident CHD in women but
not in men (hazard ratio [HR] for women = 1.7, 95%
conﬁdence interval [CI] 1.2–2.4 versus HR for men = 0.9,
95% CI 0.7–1.2). This increased CHD risk associated with
HFE mutations in women was statistically signiﬁcant in
never smokers (HR = 1.8, 95% CI 1.1–2.8) and current
smokers (HR = 3.1, 95% CI 1.4–7.1), but not in former
smokers (HR = 1.3, 95% CI 0.7–2.4). HFE mutations are
associated with increased risk of incident CHD in women.
Keywords HFE mutation  Hemochromatosis 
Coronary heart disease  Smoking  Gender
Introduction
Hereditary hemochromatosis is a genetic disorder charac-
terized by iron overload [1]. Iron overload in patients with
hereditary hemochromatosis results in iron depots in the
pancreas, liver, joints and heart. In the heart, such depots
have been associated with coronary heart disease (CHD)
and shortened life expectancy [2]. The most common cause
of hereditary hemochromatosis are two common mutations
in the HFE gene, C282Y and H63D [3, 4]. Over 80% of the
patients with hereditary hemochromatosis are homozygous
for the C282Y mutation, about 1% are homozygous for the
H63D mutation and about 7% are compound heterozygous
[1]. In populations of European origin, an estimated 0.4%
of the population is homozygous and 9% is heterozygous
carrier of the C282Y mutation and 13% is homozygous and
2% heterozygous for the H63D mutation [1].
Complications of iron overload may not only occur to
homozygous carriers of the risk alleles. Compound hetero-
zygotes and heterozygotes for the C282Y and H63D muta-
tions also have a subtle increases in serum iron, serum
ferritinandtransferrinsaturation[5–8].Theseslightchanges
suggest that heterozygotes are more likely to have a slow
accumulation of iron, which may lead to pathology later in
life. Iron deposits in the arterial wall trigger the low density
lipoprotein cholesterol peroxidation and therefore contrib-
utes the formation of atherosclerotic lesions and to the
inﬂammation leading to cardiovascular disease [1, 2]. Some
studies also showed that C282Y carriers had an increased
risk of myocardial infarction [3], and coronary heart disease
(CHD) [4]. Similarly, smoking has also been associated to
cardiovascular disease through increased inﬂammation,
thrombosis, and oxidation of low-density lipoprotein cho-
lesterol [6]. Therefore, to properly disentangle the associa-
tion between HFE mutations and cardiovascular disease
requires taking into account the effect of smoking. Follow-
ing this, previous work of our group also showed an
increased risk of stroke among HFE carriers who smoked
[5].Theaimofthepresentstudywastoexaminetheeffectof
the two common HFE C282Y and H63D mutations on
incident CHD accounting for the effect of smoking. Since
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ogy by menstruation, we examined men and women
separately.
Methods
Study population
The present analysis was performed within the Rotterdam
Study, an ongoing population-based study on the determi-
nants of disease and disability in 7,983 subjects aged
55 years and older. Design, rationale and details of the
study have been described previously [9]. The present
analyses used baseline data (collected between 1990 and
1993) and follow-up morbidity and mortality data (col-
lected until December 2001; mean follow-up of 8.3 years,
standard deviation (SD) 2.7 years). The Medical Ethics
Committee of the Erasmus MC University Medical Center
approved the study protocol and all participants provided
written informed consent.
Data collection
Baseline data collection
During home visits, a trained interviewer obtained informa-
tion on health status, medical history, medication use and
smoking status at baseline. Subsequently, participants were
invitedtothestudycenterwheretheyunderwentanextensive
clinical examination in which height, weight, systolic and
diastolic blood pressures were measured. Body mass index
(BMI) was computed as weight (kg) divided by height
squared (m
2). Systolic and diastolic blood pressures were
measured twice in sitting position, after 5 min rest, using a
random-zero sphygmomanometer. The mean of the two
measurements was used for the analysis. Hypertension was
deﬁned as systolic blood pressure higher than 160 mm Hg,
diastolicbloodpressure higher than100 mmHgorthe use of
medication indicated to treat high blood pressure (hyperten-
sion grades 2 and 3) [10]. Serum glucose, total cholesterol,
high-density lipoproteins (HDL) cholesterol and C-reactive
protein levels, as a marker of inﬂammation, were determined
using an automated enzymatic procedure [11, 12]. Diabetes
was diagnosed based on the use of medication, and/or a
random or post-load glucose levels higher than 11.1 mmol/L
[13]. Iron and ferritin levels and transferrin saturation were
determined in subgroup as previously described [6].
Follow-up assessment
During follow-up, information on fatal and non-fatal car-
diovascular endpoints was obtained from the general
practitioners and hospital records. Two research physicians
and a cardiologist independently reviewed all information
and classiﬁed all the events according to the International
Classiﬁcation of Diseases, 10th edition (ICD-10) [14].
Incident CHD was deﬁned as the occurrence of non-fatal
myocardial infarction (ICD-10 code I21), revascularization
procedure (percutaneous transluminal coronary angioplasty
or coronary artery bypass graft) and cardiac death. Cardiac
death was deﬁned as death caused by myocardial infarction
or other ischemic heart disease (ICD-10 codes I20–I25),
sudden cardiac death (ICD-10 code I46), cardiac arrhyth-
mias (ICD-10 code I49), sudden death undeﬁned (ICD-10
code R96) or death from heart failure (ICD-10 code I50).
Genotyping of HFE mutations
C282Y and H63D mutations were genotyped in a random
sample of 3,798 individuals as described in details previ-
ously [15]. Baseline characteristics did not differ between
randomly selected and non-selected participants.
Statistical analysis
From the 3,798 individuals who had C282Y and H63D
genotype available, 3,435 had complete information on
cardiovascular risk factors at baseline and were included in
the analyses. There were only 10 homozygotes for the
C282Y and 80 homozygotes for the H63D mutation among
which 2 and 11 cases of incident CHD, respectively. Pre-
vious studies on the HFE mutations and iron parameters
showed that serum iron, serum ferritin and transferrin sat-
uration were similar for C282Y and H63D heterozygotes
[5, 6]. Therefore, we pooled carriers of C282Y or H63D
mutations as HFE carriers. Differences in baseline char-
acteristics between the HFE carriers and non-carriers were
tested using Chi-squared statistics (for categorical vari-
ables) or t tests (for continuous variables). Variables that
were not normally distributed, are presented as median
with interquartile range and analyzed using the Mann–
Whitney U test. CHD incidence rates were calculated as
number of events per 1,000 person-years. Risks of incident
CHD were quantiﬁed as hazard ratios (HRs) from Cox
proportional hazards models using age as time scale [16].
Survival time was calculated from age at baseline to age at
event. HRs were calculated crude and adjusted for sex,
smoking status, hypertension, BMI, total serum cholesterol,
HDL cholesterol, diabetes mellitus and CHD at baseline.
Further, HRs were additionally adjusted for C reactive
protein, to evaluate the role of inﬂammation in the rela-
tionship between HFE mutations and incident CHD. The
association between HFE mutations and the risk of incident
CHD was investigated overall and in sex and smoking
subgroups given that both are associated with CHD and the
644 M. C. Pardo Silva et al.
123clinical manifestations of iron overload in our study [15].
Proportionality of all models was tested by Schoenfeld
residuals [17]. P-values lower then 0.05 were considered
statistically signiﬁcant.
Results
Genotypes and allele frequencies were in Hardy–Weinberg
equilibrium (C282Y: CC 88.1%, CY 11.6%, YY 0.3%,
P = 0.41; H63D: HH 73.2%, HD 24.5%, DD 2.4%,
P = 0.25). At baseline, women had lower prevalence of
smoking, hypertension and myocardial infarction and a
highermeanBMIcomparedtomen.Baselinecharacteristics
by genotype are presented in Table 1. Carriers and non-
carriers of the HFE mutations did not signiﬁcantly differ in
risk factors for cardiovascular disease with three exceptions
in women. In women, HFE carriers had higher median body
mass index (27.0 versus 26.6 kg/m
2; P = 0.05), higher
median C-reactive protein levels than non-carriers
(2.0 versus 1.7 mg/dL; P = 0.05) and a lower frequency of
diabetes mellitus (10% versus 13%; P = 0.05). HFE carri-
ers had higher levels of iron and ferritin and higher trans-
ferrin saturation than non-carriers (Table 2). This difference
was statistically signiﬁcant for both iron levels and trans-
ferrin saturation in men and women. A similar trend was
observed within smoking strata, although the differences
were not statistically signiﬁcant (Data not shown). Figure 1
shows that females HFE carriers tend to have higher C-
reactive protein levels than non-carriers, particularly among
current or former smokers (P = 0.08). In men, no differ-
ences in C-reactive protein levels between HFE carriers and
non-carriers were observed.
During follow-up, 483 participants developed incident
CHD. Men had higher CHD incidence than women
(25.3 versus 11.8 cases/1,000 person years, P\0.001;
Table 3). HFE mutations were associated with an increased
risk of incident CHD in women (HRcrude [95% CI] = 1.3
[1.0–1.8]), but not in men (HRcrude [95% CI] = 0.9
[0.7–1.2]). Further adjustment by co-variates including
smoking status lead to an increase in the risk of CHD in
women (HRadjusted [95% CI] = 1.7 [1.2–2.4]), but not in
men (HRadjusted [95% CI] = 0.9 [0.7–1.2]). Additionally to
HFE status, history of myocardial infarction, diabetes mel-
litus at baseline and smoking were important risk factors for
CHD in women. In men, serum cholesterol level and high-
density lipoprotein level, diabetes mellitus and history of
myocardial infarction were key risk factors for CHD. This
increased CHD risk associated with HFE mutations in
women was statistically signiﬁcant in current smokers
(HR = 3.1,95%CI 1.4–7.1) andnever smokers (HR = 1.8,
95%CI1.1–2.8),butnotinformersmokers(HR = 1.3,95%
CI 0.7–2.4; Table 4). Exclusion of the homozygous and
compound heterozygous carriers did not change the results
(Data not shown). The interaction term HFE status *
smoking status was not statistically signiﬁcant.
Table 1 Baseline characteristics by sex and HFE carrier status
Women Men
HFE-carriers
(n = 656)
Non-carriers
(n = 1,174)
P-value HFE-carriers
(n = 617)
Non-carriers
(n = 988)
P-value
Age at entry (years) 69.3 (9.0) 69.6 (9.2) 0.46 67.7 (7.8) 68.0 (7.6) 0.39
Smoking status
Current smokers 105 (16%) 242 (21%) 193 (31%) 288 (29%)
Former smokers 187 (29%) 333 (28%) 0.43 367 (59%) 638 (65%) 0.46
Never smokers 364 (55%) 599(51%) 57 (9%) 62 (6%)
Systolic blood pressure (mm Hg) 139.9 (21.7) 139.3 (23.2) 0.62 138.4 (21.3) 138.5 (22.5) 0.95
Diastolic blood pressure (mm Hg) 73.6 (11.5) 73.1 (11.6) 0.32 75.1 (11.8) 74.1 (11.7) 0.12
Hypertension 405 (62%) 735 (63%) 0.61 416 (68%) 675 (68%) 0.73
Body mass index (kg/m
2) 27.0 (4.3) 26.6 (3.9) 0.05 25.8 (3.0) 25.7 (3.0) 0.60
Diabetes mellitus 66 (10%) 154 (13%) 0.05 80 (13%) 111 (11%) 0.30
Total serum cholesterol (mmol/L) 6.83 (1.2) 6.85 (1.2) 0.72 6.28 (1.3) 6.35 (1.1) 0.26
HDL cholesterol (mmol/L) 1.44 (0.4) 1.42 (0.4) 0.41 1.19 (0.3) 1.22 (0.3) 0.07
C-reactive protein (mg/L)
a 2.0 (0.9-3.7) 1.7 (0.9-3.3) 0.05 1.9 (0.9-3.9) 1.9 (0.9-3.8) 0.72
Myocardial infarction at baseline 66 (11%) 152 (13%) 0.18 147 (25%) 232 (24%) 0.74
Values are means (standard deviations) for continuous variables and numbers (percentages) for categorical variables. P-values were obtained by
t-test for continuous variables, v
2 for categorical variables, and Mann–Whitney U test for C-reactive protein. HDL high density lipoprotein
a Median (interquartile range)
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We have found that the HFE mutations are associated with
higher risk of incident CHD in women. C-reactive protein,
a strong predictor of CHD risk was not associated with
HFE mutations in women with current or former smoking
history. Our study was embedded in a large follow-up
study of Caucasian individuals aged 55 and older. This
long follow-up allows us to study outcomes that are the
result of lifelong exposures and express at older ages like
cardiovascular disease associated with iron overload.
A previous report based on a smaller sample of the
Rotterdam study (n = 342) showed that HFE genotypes,
also those who were heterozygous, were associated with
higher levels of transferrin saturation and serum iron levels,
albeit that levels in those homozygous for the mutations are
exponentially higher [6]. Previous work of our group also
showed an increased risk of stroke among HFE carriers
who smoked [15]. Altogether, these results are in line with
the mechanism linking HFE mutations and smoking to
cardio- and cerebrovascular disease through damage to
vessel wall and inﬂammation [15]. The underlying mech-
anism linking HFE and CHD is thought to be through iron-
related oxidative stress and the subsequent damage to
vessel wall and inﬂammation [15, 18]. Such mechanism is
also supported by endothelial dysfunction observed in
normal subjects after receiving intravenous iron sucrose
reported recently [19], as well as the positive association
between markers of oxidative stress and iron therapy [20].
Despite the solid grounds for this association, our data
showed that CRP levels were not an intermediate factor in
this association. A previous study on the association of
chronic inﬂammation and hemochromatosis phenotype
revealed that CRP levels did not change between homo-
zygotes for the C282Y mutations with high or low iron
stores [21]. Most likely, blood CRP level is a biomarker for
generalized inﬂammation not speciﬁc to the association
HFE and CHD. How and through which early intermediate
inﬂammatory pathways HFE is related to inﬂammation,
remains to be determined.
Another issue to be explained is the fact we only found
signiﬁcant evidence for association of HFE and CHD in
women and not in men. While there is an ongoing dis-
cussion of the validity of subgroup testing by sex in genetic
studies [22], there are reasons to separate men and women
for HFE. First, phlebotomy is the key strategy for pre-
vention of hemochromatosis and women are therefore
naturally protected due to their menstruation [23]. While
this is a common explanation for sex-differences in CHD
risk associated with HFE mutations, in our study an
increased risk was found in female carriers rather than in
male carriers. This may be related to the study design. We
studied elderly people and therefore male carriers may
have been selected out from the population due to early
Table 2 Iron parameters by sex and HFE carrier status
Women Men
HFE-carriers
(n = 37)
Non-carriers
(n = 130)
P-value HFE-carriers
(n = 35)
Non-carriers
(n = 124)
P-value
Iron (lmol/L) 18.0 (14.0–21.0) 14.0 (13.0–18.5) 0.02 20.0 (15.3–23.0) 16.0 (13.0–20.0) \0.01
Ferritin (lg/L) 141.5 (79.5–218.0) 109.0 (76.5–223.0) 0.39 194.0 (107.0–358.0) 187.0 (86.0–275.0) 0.22
Transferrin saturation (%) 29.9 (23.6–35.5) 23.4 (20.1–29.1) \0.01 33.7 (25.4–41.8) 27.2 (22.0–31.6) \0.01
Values are medians (interquartile range). P-values were obtained by Mann–Whitney U test
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Fig. 1 Median C-reactive protein (CRP) levels and interquartile
range by HFE genotype and smoking status for men and women
646 M. C. Pardo Silva et al.
123mortality related to HFE. In women, the gene effect is
likely to express clinically later as they are protected by
menstruation up to menopause. Second, it also should be
noted that the major risks factors for CHD are smoking,
body mass index, diabetes and lipid proﬁle as supported by
the effect of these co-variates when adjusting HR for CHD
in women and men. The extent of CHD risk conferred by
these factors is of such magnitude that the genetic predis-
position associated with HFE carrier status is rapidly out-
weighed as seen in Table 4 where it is shown that greater
CHD risk is associated with smoking status rather than
with HFE mutations. Given the higher prevalence of
smoking (current and former) among men compared to
women at baseline, it is likely that the modest effect of
Table 3 Incidence rates and hazard ratios for incident coronary heart disease by sex and HFE carrier status
CHD Follow-up (py) Incidence rate Hazard ratio (95% CI)
(CHD/1,000 py) Crude Adjusted
a
Women
All 177 15,020 11.8 (10.2 to 13.7)
HFE-carriers 73 5,370 13.6 (10.8 to 17.1) 1.3 (1.0 to 1.8) 1.7 (1.2 to 2.4)
Non-carriers 104 9,650 10.8 (8.9 to 13.1)
Men
All 306 12,093 25.3 (22.6 to 28.3)
HFE-carriers 116 4,735 24.5 (20.4 to 29.4) 0.9 (0.7 to 1.2) 0.9 (0.7 to 1.2)
Non-carriers 190 7,358 25.8 (22.4 to 29.8)
a Adjusted for body mass index, hypertension, diabetes mellitus, smoking status at baseline, total and high density lipoprotein cholesterol,
C-reactive protein and myocardial infarction at baseline
CHD coronary heart disease, py person-years, CI conﬁdence interval
Table 4 Incidence rates and hazard ratios for incident coronary heart disease by sex, smoking status and HFE carrier status
CHD Follow-up (py) Incidence rate (CHD/1,000 py) Hazard ratio (95% CI)
Crude Adjusted
a Adjusted
a
Women
Never smokers
Non-carriers 50 4.817 10.4 (7.9–13.7) Reference Reference Reference
HFE-carriers 37 2.938 12.6 (9.1–17.4) 1.3 (0.9–2.0) 1.8 (1.1–2.8) 1.8 (1.1–2.8)
Former smokers
Non-carriers 33 2.783 11.9 (8.4–16.7) 1.6 (1.0–2.5) 1.9 (1.1–3.1) Reference
HFE-carriers 20 1.584 12.6 (8.1–19.6) 1.7 (1.0–3.0) 2.2 (1.2–4.0) 1.3 (0.7–2.4)
Current smokers
Non-carriers 21 2.05 10.2 (6.7–15.7) 1.6 (1.0–2.8) 1.4 (0.8–2.7) Reference
HFE-carriers 16 848 18.9 (11.6–30.8) 3.1 (1.7–5.6) 3.9 (2.1–7.3) 3.1 (1.4–7.1)
Men
Never smokers
Non-carriers 9 477 18.9 (9.8–36.3) Reference Reference Reference
HFE-carriers 8 440 18.2 (9.1–36.3) 0.9 (0.3–2.3) 0.6 (0.2–1.8) 0.6 (0.2–1.8)
Former smokers
Non-carriers 132 4.801 27.5 (23.2–32.6) 1.4 (0.7–2.8) 1.2 (0.6–2.5) Reference
HFE-carriers 67 2.902 23.1 (18.2–29.3) 1.2 (0.6–2.4) 1.0 (0.5–2.0) 0.8 (0.6–1.1)
Current smokers
Non-carriers 49 2.081 23.5 (17.8–31.2) 1.2 (0.6–2.5) 1.1 (0.5–2.2) Reference
HFE-carriers 41 1.392 29.4 (21.7–40.0) 1.5 (0.7–3.2) 1.3 (0.6––2.8) 1.2 (0.8–1.9)
a Adjusted for body mass index, hypertension, diabetes mellitus, total and high density lipoprotein cholesterol, C-reactive protein and myo-
cardial infarction at baseline
CHD coronary heart disease, py person-years, CI conﬁdence interval
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123HFE mutations on the risk of CHD is only apparent among
women.
Because of their role in iron overload and their impact
on CHD risk, HFE mutations have been of interest in
public health [7, 24–29], For long, they have been viewed
as a model for genetic testing. A genetic-based strategy for
prevention of iron overload and its complications has been
investigated after the identiﬁcation of the two common
mutations in the HFE gene [30]. The small effect size, the
lack of consistency in the association between HFE
mutations and cardiovascular disease and mortality
[31–44], and the possible effect modiﬁcation by environ-
mental factors such as smoking [15, 31–35] implies that the
beneﬁt of such screening program varies between different
subgroups, imposing further difﬁculties to the use of
genetic testing for population-based screening. The results
of our study conﬁrm these previous ﬁndings and do not
support genetic screening on HFE mutations.
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